The Effect of GnRH Agonist Administered in the Luteal Phase on ART Cycle Outcomes
NCT ID: NCT02114645
Last Updated: 2014-04-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
100 participants
INTERVENTIONAL
2014-04-30
2015-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Timing of Estrogen Support During the Luteal Phase of in Vitro Fertilization (IVF)/Intracytoplasmic Sperm Injection (ICSI) Cycle
NCT01367912
GnRH Agonist for Luteal Phase Support.
NCT05484193
Comparison Between Natural and Artificial Cycle in Recipient Oocyte Patients
NCT01353846
rFSH vs rFSH+rLH in Dydrogesterone-Based Progestin Protocol: A Prospective Study
NCT07348757
Oral Dydrogesterone vs. Micronized Vaginal Progesterone for Luteal Phase Support in Frozen-thawed Embryo Transfer Cycles
NCT04124913
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
CROSSOVER
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
LongGnRH agonist protocol(controlgroup)
Long GnRH agonist protocol ( control group) Luteal Phase Support: Vaginal progesterone + 4mg oral estradiol valerate
vaginal progesterone
crinone gel is applied till fetal heart beat is detected
4 mg oral estradiol valerate
estrofem is given twice a day
Long protocol-leuprolide acetate
Long GnRH agonist protocol Luteal Phase Support: Vaginal progesterone+oral estradiol valerate subcutaneous 0.5mg leuprolide acetate fifth and tenth day after embryo transfer
Leuprolide acetate
in experimentals groups,on fifth and tenth day after embryo transfer 0,5mg leuprolide acetate is given subcutaneously as luteal phase support
vaginal progesterone
crinone gel is applied till fetal heart beat is detected
4 mg oral estradiol valerate
estrofem is given twice a day
GnRHantagonist protocol(control group)
GnRH antagonist protocol ( control group) Luteal Phase Support: Vaginal progesterone + 4mg oral estradiol valerate
vaginal progesterone
crinone gel is applied till fetal heart beat is detected
4 mg oral estradiol valerate
estrofem is given twice a day
antagonist protocol-leuprolide acetate
GnRH antagonist protocol Luteal Phase Support: Vaginal progesterone + 4mg oral estradiol valerate + subcutaneous 0.5mg leuprolide acetate fifth and tenth day after embryo transfer
Leuprolide acetate
in experimentals groups,on fifth and tenth day after embryo transfer 0,5mg leuprolide acetate is given subcutaneously as luteal phase support
vaginal progesterone
crinone gel is applied till fetal heart beat is detected
4 mg oral estradiol valerate
estrofem is given twice a day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Leuprolide acetate
in experimentals groups,on fifth and tenth day after embryo transfer 0,5mg leuprolide acetate is given subcutaneously as luteal phase support
vaginal progesterone
crinone gel is applied till fetal heart beat is detected
4 mg oral estradiol valerate
estrofem is given twice a day
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Couples having at least one good embryo available for transfer.
* Normoresponder
* Infertility etiology is unexplained
* ovulation triggered by intramuscular injection of 10000 IU of HCG
Exclusion Criteria
* High and poor responder patients
18 Years
38 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Zekai Tahir Burak Women's Health Research and Education Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Nagihan CENGAVER
Resident
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Nagihan Cengaver, Resident
Role: PRINCIPAL_INVESTIGATOR
Zekai Tahir Burak Women's Health Research and Education Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Zekai Tahir Burak Hospital
Ankara, Cankaya, Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Related Links
Access external resources that provide additional context or updates about the study.
Beneficial effect of luteal-phase GnRH agonist administration on embryo implantation after ICSI in both GnRH agonist- and antagonist-treated ovarian stimulation cycles.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ZTB5030
Identifier Type: REGISTRY
Identifier Source: secondary_id
ZTB-5030
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.